|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.76 CHF | -0.69% |
|
-4.58% | +4.58% |
| 12-10 | Swiss Equities Extend Losses; KOF Global Economic Barometers Stable | MT |
| 12-10 | Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment | MT |
| Capitalization | 201B 191B 177B 158B 285B 17,073B 316B 2,210B 816B 7,010B 755B 739B 30,593B | P/E ratio 2024 * |
18.3x | P/E ratio 2025 * | 15.7x |
|---|---|---|---|---|---|
| Enterprise value | 214B 204B 189B 168B 304B 18,201B 337B 2,356B 870B 7,474B 805B 788B 32,615B | EV / Sales 2024 * |
4.25x | EV / Sales 2025 * | 4.07x |
| Free-Float |
87.19% | Yield 2024 * |
3.75% | Yield 2025 * | 3.89% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novartis AG
More recommendations
More press releases
More news
| 1 day | -0.69% | ||
| 1 week | -4.58% | ||
| Current month | -4.84% | ||
| 1 month | -4.42% | ||
| 3 months | -10.17% | ||
| 6 months | -5.87% | ||
| Current year | +4.58% |
1 week
88.72
91.23
1 month
88.7293.99
Current year
83.63102.72
1 year
83.63102.72
3 years
72.84102.72
5 years
65.09102.72
10 years
65.09103.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 31/01/2018 | |
| Director of Finance/CFO | 59 | 23/04/2013 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 15/05/2022 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Sawyers
BRD | Director/Board Member | 65 | 31/12/2012 |
Bill Winters
BRD | Director/Board Member | 63 | 31/12/2012 |
| Chairman | 68 | 31/12/2012 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | - | |
| 5.57% | 20 M€ | +16.00% | - | |
| 3.79% | 2 M€ | -25.75% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.69% | -4.58% | +4.77% | +18.89% | 204B | ||
| -0.50% | -1.69% | +33.70% | +227.51% | 724B | ||
| +0.03% | +0.03% | +17.04% | +108.39% | 491B | ||
| -0.25% | -2.05% | -3.36% | -9.83% | 360B | ||
| -0.51% | -3.21% | +17.68% | +40.01% | 312B | ||
| -2.69% | -0.83% | -2.65% | +39.08% | 263B | ||
| -1.32% | -0.28% | +0.20% | -32.68% | 236B | ||
| -1.78% | -2.58% | +3.85% | +28.30% | 212B | ||
| -0.68% | -0.92% | +2.46% | +30.76% | 149B | ||
| -2.03% | +0.04% | -11.15% | -51.55% | 148B | ||
| Average | -0.55% | -1.33% | +6.25% | +39.89% | 309.81B | |
| Weighted average by Cap. | -0.44% | -1.31% | +11.91% | +76.23% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 50.42B 47.99B 44.47B 39.55B 71.4B 4,278B 79.13B 554B 204B 1,757B 189B 185B 7,666B | 52.6B 50.07B 46.4B 41.27B 74.5B 4,464B 82.56B 578B 213B 1,833B 197B 193B 7,999B |
| Net income | 11.04B 10.51B 9.74B 8.66B 15.64B 937B 17.33B 121B 44.77B 385B 41.45B 40.56B 1,679B | 12.51B 11.91B 11.03B 9.81B 17.71B 1,061B 19.63B 137B 50.71B 436B 46.96B 45.95B 1,902B |
| Net Debt | 13.3B 12.65B 11.73B 10.43B 18.83B 1,128B 20.87B 146B 53.91B 463B 49.92B 48.84B 2,022B | 12.69B 12.08B 11.19B 9.96B 17.97B 1,077B 19.92B 139B 51.45B 442B 47.64B 46.61B 1,930B |
More financial data
* Estimated data
Employees
76,057
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/12/24 | 88.76 CHF | -0.69% | 3,171,761 |
| 09/12/24 | 89.38 CHF | -0.48% | 3,006,728 |
| 06/12/24 | 89.81 CHF | -0.63% | 2,468,013 |
| 05/12/24 | 90.38 CHF | +0.31% | 3,554,663 |
| 04/12/24 | 90.10 CHF | -3.14% | 4,670,823 |
Delayed Quote Swiss Exchange, December 10, 2024 at 04:30 pm
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
100.63USD
Average target price
115.30USD
Spread / Average Target
+14.58%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVN Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition